BrainsWay Ltd. (TLV: BWAY)
Israel
· Delayed Price · Currency is ILS · Price in ILA| Market Cap | 485.00M |
| Revenue (ttm) | 137.17M |
| Net Income (ttm) | 2.29M |
| Shares Out | 33.36M |
| EPS (ttm) | 0.07 |
| PE Ratio | 215.15 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 42,437 |
| Open | 1,460.00 |
| Previous Close | 1,440.00 |
| Day's Range | 1,440.00 - 1,464.00 |
| 52-Week Range | 652.10 - 1,493.00 |
| Beta | 0.32 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 14, 2024 |
About BrainsWay
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves doctors, hospi... [Read more]
Financial Performance
In 2023, BrainsWay's revenue was $31.79 million, an increase of 16.96% compared to the previous year's $27.18 million. Losses were -$4.20 million, -68.56% less than in 2022.
Financial numbers in USD Financial StatementsNews
Israel Ministry of Defense Clears BrainsWay Deep TMS™ for PTSD Reimbursement at Israeli Hospitals
BURLINGTON, Mass. and JERUSALEM, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulatio...
BrainsWay appoints Richard Bermudes, M.D. as CMO
BrainsWay (BWAY) has announced the appointment of Richard A. Bermudes, M.D. as Chief Medical Officer, effective Sept. 1, 2024
BrainsWay Appoints Richard A. Bermudes, M.D.
Dr. Bermudes is Widely Considered One of the Preeminent U.S. Clinicians in the TMS Field Dr. Bermudes is Widely Considered One of the Preeminent U.S. Clinicians in the TMS Field
BrainsWay: Operating Leverage Driving Upside
BrainsWay Ltd. (BWAY) Q2 2024 Earnings Call Transcript
BrainsWay Ltd. (NASDAQ:BWAY) Q2 2024 Earnings Call Transcript August 6, 2024 8:30 AM ET Company Participants Brian Ritchie - IR, LifeSci Advisors Hadar Levy - CEO Ido Marom - CFO Conference Call Part...
BrainsWay Reports Second Quarter 2024 Financial Results and Operational Highlights
Generated Robust 28 % Year-over-Year Revenue Growth in Q2 2024 Recorded Positive Quarterly Net Income for Third Consecutive Quarter, and Positive Adjusted EBITDA and Cash Flow from Operations for Four...
BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024
BURLINGTON, Mass. and JERUSALEM, July 23, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...
BrainsWay Expands Global Imprint with Exclusive Multi-Year Distribution Agreement in Canada
BURLINGTON, Mass. and JERUSALEM, June 17, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...
BrainsWay Launches Prospective, Randomized, Controlled, Multicenter Trial Evaluating Accelerated Deep TMS™ for Depression
Shortened Acute Treatment Period Could Enhance Appeal and Market Opportunities of Deep TMS™ Shortened Acute Treatment Period Could Enhance Appeal and Market Opportunities of Deep TMS™
BrainsWay Receives Expanded FDA Labeling to Treat Late Life Depression
Deep TMS™ Becomes the First and Only TMS Device Indicated for Depression Treatment in Patients Between the Ages of 68 and 86 Deep TMS™ Becomes the First and Only TMS Device Indicated for Depression Tr...
BrainsWay: Cash Flows Are Underappreciated
BrainsWay reported strong Q1 results with profitability, positive cash flow, and strong growth. Market conditions have supposedly affected Neuronetics, but BrainsWay has not experienced similar proble...
BrainsWay Ltd. (BWAY) Q1 2024 Earnings Call Transcript
BrainsWay Ltd. (NASDAQ:BWAY) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Company Participants Troy Williams – Investor Relations, Life Science Advisors Hadar Levy – Chief Executive Office...
BrainsWay Reports First Quarter 2024 Financial Results and Operational Highlights
Generated Significant 37% Year-over-Year Revenue Growth in Q1 2024 Recorded Positive Quarterly Net Income for Second Consecutive Quarter, and Positive Adjusted EBITDA and Cash Flow from Operations for...
BrainsWay to Report First Quarter 2024 Financial Results on May 8, 2024
BURLINGTON, Mass. and JERUSALEM, April 24, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatm...
BrainsWay Announces Published Review Results Highlighting Potential of Deep TMS™ to Treat Parkinson's Disease
Clinical Data from Multiple Trials Showed Improvements in Both Motor and Non-Motor Symptoms Clinical Data from Multiple Trials Showed Improvements in Both Motor and Non-Motor Symptoms
BrainsWay Broadens Partnership with Katie's Way Plus Through Order of an Additional 18 Deep TMS™ Systems
Katie's Way Provides Lifesaving Mental Health Treatment Nationally with a Focus on Servicemembers, Veterans, and their Families Katie's Way Provides Lifesaving Mental Health Treatment Nationally with ...
BrainsWay Ltd. (BWAY) Q4 2023 Earnings Call Transcript
BrainsWay Ltd. (NASDAQ:BWAY) Q4 2023 Earnings Conference Call March 6, 2024 8:30 AM ET
BrainsWay Reports Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights
Generated Record Revenues with Robust 50% Year-over-Year Revenue Growth in Q4 2023; Generated Positive Quarterly Net Income
BrainsWay to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
BURLINGTON, Mass. and JERUSALEM, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...
BrainsWay Initiates Clinical Evaluation of Rotational Field “Deep TMS 360°™” Technology
BURLINGTON, Mass. and JERUSALEM, Jan. 10, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...
BrainsWay Highlights Expanded Deep TMS™ Access with Growing Western U.S. Network
BURLINGTON, Mass. and JERUSALEM, Dec. 19, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...
BrainsWay Announces Continued Expansion of Deep TMS™ in South Korea
BURLINGTON, Mass. and JERUSALEM, Dec. 07, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...
Louisiana Insurer Expands Deep TMS™ Access for 1.9 Million Covered Lives
BURLINGTON, Mass. and JERUSALEM, Nov. 20, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...
BrainsWay: Positive Cash Flow And Continued Growth
BrainsWay reported solid results in Q3 2023 and is now on the verge of sustainable profitability. BrainsWay's focus on larger organizations appears to be supporting growth and improving sales efficien...
Brainsway Ltd (BWAY) Q3 2023 Earnings Call Transcript
Brainsway Ltd (NASDAQ:BWAY) Q3 2023 Earnings Conference Call November 15, 2023 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Hadar Levy - Chief Executive Office...